Characterization of bevacizumab dose response relationship in U87 brain tumors using magnetic resonance imaging measures of enhancing tumor volume and relative cerebral blood volume.

Pechman KR, Donohoe DL, Bedekar DP, Kurpad SN, Hoffmann RG, Schmainda KM
J Neurooncol. 2011 105 (2): 233-9

PMID: 21533524 · PMCID: PMC4323180 · DOI:10.1007/s11060-011-0591-8

Despite the early promising results with the anti-angiogenic agent, bevacizumab, to prolong time to progression in patients with brain tumors, the optimal dose and drug combinations have not yet been defined. The purpose of this study was to characterize the bevacizumab dose-response relationship for brain tumors by measuring the contrast-agent enhanced tumor volumes and relative cerebral blood volume (rCBV) using dynamic susceptibility contrast (DSC) imaging. The studies, performed in the U87 brain tumor model using doses of bevacizumab ranging from 0 to 10 mg/kg, demonstrate that tumor growth and vascularity are inhibited at all doses used, compared to untreated controls. However, only the maximum dose showed a statistically significant difference in growth rate. Conversely tumor vascularity, as measured with rCBV, was inhibited equally well for all doses used with no clear indication that higher doses are more effective.

MeSH Terms (16)

Angiogenesis Inhibitors Animals Antibodies, Monoclonal, Humanized Bevacizumab Blood Volume Brain Neoplasms Contrast Media Dose-Response Relationship, Drug Gadolinium DTPA Glioblastoma Humans Magnetic Resonance Imaging Male Rats Tumor Burden Tumor Cells, Cultured

Connections (1)

This publication is referenced by other Labnodes entities:

Links